ETFs Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2025 BST			5-day change	1st Jan Change
4.990 ^USD	-0.60%		+0.40%	+4.18%

06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Value-Defensive Index	CI
06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Defensive Index	CI

ETFs positioned on Vanda Pharmaceuticals Inc.

Name	Weight	AuM	1st Jan change
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	0.34%	29 M€	-1.22%	-
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	0.22%	23 M€	-2.11%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	89 M€	+0.71%	-
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0.01%	9 M€	+5.53%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0%	293,477 M€	-0.02%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0%	22 M€	+2.32%	-

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

368

Sector

Biotechnology & Medical Research

Calendar

07-23 - Q2 2025 Earnings Release (Projected)

More about the company